Bone Biologics Corp

Company Profile

Bone Biologics Corp had its IPO on 2016-03-31 under the ticker symbol BBLG.

The company operates in the Healthcare sector and Medical Devices industry. Bone Biologics Corp has a staff strength of 2 employees.

Stock update

Shares of Bone Biologics Corp opened at $0.65 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.62 - $0.68, and closed at $0.64.

This is a -4.48% slip from the previous day's closing price.

A total volume of 84,655 shares were traded at the close of the day’s session.

In the last one week, shares of Bone Biologics Corp have slipped by -4.62%.

Bone Biologics Corp's Key Ratios

Bone Biologics Corp has a market cap of $3.31 million, indicating a price to book ratio of 0.9268 and a price to sales ratio of 0.

In the last 12-months Bone Biologics Corp’s revenue was $0 with a gross profit of $0 and an EBITDA of $-824964. The EBITDA ratio measures Bone Biologics Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Bone Biologics Corp’s operating margin was 0% while its return on assets stood at -59.44% with a return of equity of -102.26%.

In Q1, Bone Biologics Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Bone Biologics Corp’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.33 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bone Biologics Corp’s profitability.

Bone Biologics Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -6.6371. Its price to sales ratio in the trailing 12-months stood at 0.

Bone Biologics Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$6.78 million

Total Liabilities

$4.01 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Bone Biologics Corp ended 2024 with $6.78 million in total assets and $0 in total liabilities. Its intangible assets were valued at $6.78 million while shareholder equity stood at $2.77 million.

Bone Biologics Corp ended 2024 with $0 in deferred long-term liabilities, $4.01 million in other current liabilities, 16701.00 in common stock, $-75670126.00 in retained earnings and $0 in goodwill. Its cash balance stood at $6.19 million and cash and short-term investments were $6.19 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Bone Biologics Corp’s total current assets stands at $6.78 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.

In 2024, Bone Biologics Corp's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Bone Biologics Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.64

52-Week High

$1.97

52-Week Low

$0.14

Analyst Target Price

$4.9

Bone Biologics Corp stock is currently trading at $0.64 per share. It touched a 52-week high of $1.97 and a 52-week low of $1.97. Analysts tracking the stock have a 12-month average target price of $4.9.

Its 50-day moving average was $1.11 and 200-day moving average was $5.64 The short ratio stood at 1.27 indicating a short percent outstanding of 0%.

Around 4014.3% of the company’s stock are held by insiders while 1831% are held by institutions.